News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
85 Results
Type
Article (10)
Press Release (75)
Section
Business (33)
Deals (1)
Drug Development (22)
FDA (3)
Job Trends (1)
News (51)
Policy (2)
Tag
Academia (1)
Alliances (4)
Approvals (3)
Clinical research (8)
Earnings (16)
Events (26)
FDA (3)
IPO (1)
Job creations (1)
NextGen Class of 2024 (1)
Northern California (1)
People (14)
Phase I (6)
Phase II (7)
Phase III (2)
Pipeline (2)
Preclinical (8)
Real estate (1)
Regulatory (2)
Southern California (1)
Startups (2)
United States (6)
Date
Last 7 days (1)
Last 30 days (2)
Last 365 days (17)
2024 (16)
2023 (15)
2022 (27)
2021 (18)
2020 (2)
2019 (4)
2018 (3)
Location
Asia (4)
California (1)
Europe (4)
Florida (3)
Maryland (2)
Northern California (1)
Southern California (1)
85 Results for "wugen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association 2024 Hybrid Congress
Wugen, Inc. announces positive Phase 2 results for the company’s investigational anti-CD7 CAR-T therapy, WU-CART-007, in patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma.
June 14, 2024
·
6 min read
BioCapital
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license.
January 30, 2024
·
4 min read
BioMidwest
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.
March 14, 2024
·
2 min read
BioMidwest
Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June
Wugen today announced receipt of two new regulatory designations for its investigational CAR-T cell therapy, WU-CART-007, that it anticipates will expedite regulatory reviews on two continents.
May 20, 2024
·
5 min read
Business
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial OfficerDr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the Role
Wugen, Inc. announced the appointment of Keith Vendola, M.D., M.B.A., as chief financial officer, effective October 2023.
January 3, 2024
·
4 min read
BioMidwest
Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress
Wugen, Inc. today announced an oral presentation and an onsite poster presentation highlighting data from Wugen’s WU-NK-101 and WU-CART-007 programs at the European Hematology Association (EHA) 2023 Congress, taking place from June 8 – 11, 2023 in Frankfurt, Germany.
May 11, 2023
·
3 min read
Drug Development
Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition
Wugen, Inc. will be presenting four abstracts, now available online, at the American Society of Hematology Annual Meeting and Exposition Dec. 9-12.
November 2, 2023
·
5 min read
Drug Development
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today shared the latest data from its ongoing Phase 1/2 dose escalation study of WU-CART-007.
December 11, 2023
·
5 min read
Business
Wugen Announces CEO Transition
Wugen, Inc. today announced that Kumar Srinivasan Ph.D., M.B.A., has been appointed President and Chief Executive Officer, effective March 13, 2023.
March 21, 2023
·
3 min read
Business
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors.
May 10, 2023
·
3 min read
1 of 9
Next